Published in Wiley Interdiscip Rev Nanomed Nanobiotechnol on August 10, 2011
Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. Mol Pharm (2013) 0.98
Application of nanomedicine in emergency medicine; Point-of-care testing and drug delivery in twenty - first century. Daru (2012) 0.93
Molecular imaging of plaques in coronary arteries with PET and SPECT. J Geriatr Cardiol (2014) 0.79
Therapeutic Efficacy of an ω-3-Fatty Acid-Containing 17-β Estradiol Nano-Delivery System against Experimental Atherosclerosis. PLoS One (2016) 0.77
Concept of atherosclerosis velocity: is it a better measure of cardiovascular risk? Iran J Med Sci (2013) 0.75
Inflammation in atherosclerosis. Nature (2002) 28.92
Heart disease and stroke statistics--2010 update: a report from the American Heart Association. Circulation (2009) 27.89
Tumor vascular permeability and the EPR effect in macromolecular therapeutics: a review. J Control Release (2000) 14.89
Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med (2003) 13.29
Nanoshell-mediated near-infrared thermal therapy of tumors under magnetic resonance guidance. Proc Natl Acad Sci U S A (2003) 12.17
Near-infrared fluorescent type II quantum dots for sentinel lymph node mapping. Nat Biotechnol (2003) 11.09
A prospective natural-history study of coronary atherosclerosis. N Engl J Med (2011) 10.66
Evidence of RNAi in humans from systemically administered siRNA via targeted nanoparticles. Nature (2010) 10.09
In vivo imaging of quantum dots encapsulated in phospholipid micelles. Science (2002) 8.80
Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. J Am Coll Cardiol (2006) 8.27
Lipoprotein metabolism in the macrophage: implications for cholesterol deposition in atherosclerosis. Annu Rev Biochem (1983) 7.70
Early and late coronary stent thrombosis of sirolimus-eluting and paclitaxel-eluting stents in routine clinical practice: data from a large two-institutional cohort study. Lancet (2007) 7.61
Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. J Clin Invest (1994) 7.25
Microfluidic devices fabricated in poly(dimethylsiloxane) for biological studies. Electrophoresis (2003) 6.40
Nonoperative dilatation of coronary-artery stenosis: percutaneous transluminal coronary angioplasty. N Engl J Med (1979) 6.39
Matrix metalloproteinases in vascular remodeling and atherogenesis: the good, the bad, and the ugly. Circ Res (2002) 6.37
Atherosclerotic lesion size and vulnerability are determined by patterns of fluid shear stress. Circulation (2006) 5.58
Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation (2004) 5.44
Nanoparticle and targeted systems for cancer therapy. Adv Drug Deliv Rev (2004) 5.31
Cell-specific targeting of nanoparticles by multivalent attachment of small molecules. Nat Biotechnol (2005) 5.19
Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med (1997) 5.09
Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med (2007) 4.95
The response-to-retention hypothesis of early atherogenesis. Arterioscler Thromb Vasc Biol (1995) 4.60
Intravascular stents to prevent occlusion and restenosis after transluminal angioplasty. N Engl J Med (1987) 4.38
Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J (2006) 4.38
Biomarkers of cardiovascular disease: molecular basis and practical considerations. Circulation (2006) 4.35
Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation (2002) 4.31
Chip-NMR biosensor for detection and molecular analysis of cells. Nat Med (2008) 4.29
Stent thrombosis late after implantation of first-generation drug-eluting stents: a cause for concern. Circulation (2007) 4.24
Imaging of atherosclerotic cardiovascular disease. Nature (2008) 4.14
Magnetic relaxation switches capable of sensing molecular interactions. Nat Biotechnol (2002) 4.13
Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol (2005) 4.09
Initial and 6-month results of biodegradable poly-l-lactic acid coronary stents in humans. Circulation (2000) 4.05
In vivo 18F-fluorodeoxyglucose positron emission tomography imaging provides a noninvasive measure of carotid plaque inflammation in patients. J Am Coll Cardiol (2006) 3.91
Nanoparticle PET-CT imaging of macrophages in inflammatory atherosclerosis. Circulation (2007) 3.85
Molecular imaging of angiogenesis in early-stage atherosclerosis with alpha(v)beta3-integrin-targeted nanoparticles. Circulation (2003) 3.68
Accumulation of ultrasmall superparamagnetic particles of iron oxide in human atherosclerotic plaques can be detected by in vivo magnetic resonance imaging. Circulation (2003) 3.58
Patterns and mechanisms of in-stent restenosis. A serial intravascular ultrasound study. Circulation (1996) 3.58
Noninvasive vascular cell adhesion molecule-1 imaging identifies inflammatory activation of cells in atherosclerosis. Circulation (2006) 3.57
A bioabsorbable everolimus-eluting coronary stent system (ABSORB): 2-year outcomes and results from multiple imaging methods. Lancet (2009) 3.55
A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet (2004) 3.52
Noninvasive detection of macrophages using a nanoparticulate contrast agent for computed tomography. Nat Med (2007) 3.40
Can coronary angiography predict the site of a subsequent myocardial infarction in patients with mild-to-moderate coronary artery disease? Circulation (1988) 3.32
Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med (2010) 3.27
One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUS-IV trial. Circulation (2004) 3.23
Temporary scaffolding of coronary arteries with bioabsorbable magnesium stents: a prospective, non-randomised multicentre trial. Lancet (2007) 3.20
Expression of the elastolytic cathepsins S and K in human atheroma and regulation of their production in smooth muscle cells. J Clin Invest (1998) 3.17
A bioabsorbable everolimus-eluting coronary stent system for patients with single de-novo coronary artery lesions (ABSORB): a prospective open-label trial. Lancet (2008) 3.12
Novel MRI contrast agent for molecular imaging of fibrin: implications for detecting vulnerable plaques. Circulation (2001) 3.12
Correlates and long-term outcomes of angiographically proven stent thrombosis with sirolimus- and paclitaxel-eluting stents. Circulation (2006) 3.08
Detecting and assessing macrophages in vivo to evaluate atherosclerosis noninvasively using molecular MRI. Proc Natl Acad Sci U S A (2007) 2.99
Nanocrystal core high-density lipoproteins: a multimodality contrast agent platform. Nano Lett (2008) 2.98
Towards real-time intravascular endoscopic magnetic resonance imaging. JACC Cardiovasc Imaging (2010) 2.96
Vascular responses to drug eluting stents: importance of delayed healing. Arterioscler Thromb Vasc Biol (2007) 2.95
Drug-eluting stent and coronary thrombosis: biological mechanisms and clinical implications. Circulation (2007) 2.93
Role of integrins in endothelial mechanosensing of shear stress. Circ Res (2002) 2.85
Optical imaging: current applications and future directions. J Nucl Med (2007) 2.84
In vivo quantitative measurement of intact fibrous cap and lipid-rich necrotic core size in atherosclerotic carotid plaque: comparison of high-resolution, contrast-enhanced magnetic resonance imaging and histology. Circulation (2005) 2.76
Detection of vascular adhesion molecule-1 expression using a novel multimodal nanoparticle. Circ Res (2005) 2.67
The vulnerable, or high-risk, atherosclerotic plaque: noninvasive MR imaging for characterization and assessment. Radiology (2007) 2.66
In vivo imaging of proteolytic activity in atherosclerosis. Circulation (2002) 2.62
Stabilization of atherosclerotic plaques: new mechanisms and clinical targets. Nat Med (2002) 2.59
Inflammation in atherosclerosis: visualizing matrix metalloproteinase action in macrophages in vivo. Circulation (2006) 2.56
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO-2) trial. J Am Coll Cardiol (2003) 2.53
Expression of neutrophil collagenase (matrix metalloproteinase-8) in human atheroma: a novel collagenolytic pathway suggested by transcriptional profiling. Circulation (2001) 2.53
Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res (2003) 2.51
A whole blood immunoassay using gold nanoshells. Anal Chem (2003) 2.45
Macrophage expression of active MMP-9 induces acute plaque disruption in apoE-deficient mice. J Clin Invest (2005) 2.44
Atherosclerotic plaque composition: analysis with multicolor CT and targeted gold nanoparticles. Radiology (2010) 2.43
Intracoronary stenting and angiographic results: strut thickness effect on restenosis outcome (ISAR-STEREO) trial. Circulation (2001) 2.34
Plaque neovascularization is increased in ruptured atherosclerotic lesions of human aorta: implications for plaque vulnerability. Circulation (2004) 2.30
Optical visualization of cathepsin K activity in atherosclerosis with a novel, protease-activatable fluorescence sensor. Circulation (2007) 2.20
Relation of the site of acute myocardial infarction to the most severe coronary arterial stenosis at prior angiography. Am J Cardiol (1992) 2.19
Hybrid in vivo FMT-CT imaging of protease activity in atherosclerosis with customized nanosensors. Arterioscler Thromb Vasc Biol (2009) 2.15
Macrophage endocytosis of superparamagnetic iron oxide nanoparticles: mechanisms and comparison of ferumoxides and ferumoxtran-10. Invest Radiol (2004) 2.13
Synthesis of monodisperse spherical nanocrystals. Angew Chem Int Ed Engl (2007) 2.12
Endothelial and vascular smooth muscle cell function on poly(lactic-co-glycolic acid) with nano-structured surface features. Biomaterials (2004) 2.02
Detection of lipid core coronary plaques in autopsy specimens with a novel catheter-based near-infrared spectroscopy system. JACC Cardiovasc Imaging (2008) 2.01
Clinical progression of incidental, asymptomatic lesions discovered during culprit vessel coronary intervention. Circulation (2004) 2.00
Plasmonic intravascular photoacoustic imaging for detection of macrophages in atherosclerotic plaques. Nano Lett (2009) 1.99
In vivo imaging of hydrogen peroxide with chemiluminescent nanoparticles. Nat Mater (2007) 1.99
C-reactive protein and other emerging blood biomarkers to optimize risk stratification of vulnerable patients. J Am Coll Cardiol (2006) 1.96
Detection of lipid pool, thin fibrous cap, and inflammatory cells in human aortic atherosclerotic plaques by near-infrared spectroscopy. Circulation (2002) 1.94
Nanoparticles evading the reticuloendothelial system: role of the supported bilayer. Biochim Biophys Acta (2009) 1.94
Healing Achilles--sirolimus versus paclitaxel. N Engl J Med (2005) 1.91
Identifying inflamed carotid plaques using in vivo USPIO-enhanced MR imaging to label plaque macrophages. Arterioscler Thromb Vasc Biol (2006) 1.89
Heterogeneity of human macrophages in culture and in atherosclerotic plaques. Am J Pathol (2008) 1.86
In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol (2005) 1.85
Anisotropic mechanical properties of tissue components in human atherosclerotic plaques. J Biomech Eng (2004) 1.83
MRI to detect atherosclerosis with gadolinium-containing immunomicelles targeting the macrophage scavenger receptor. Magn Reson Med (2006) 1.79
In vivo quantum-dot toxicity assessment. Small (2010) 1.78
Recombinant HDL-like nanoparticles: a specific contrast agent for MRI of atherosclerotic plaques. J Am Chem Soc (2004) 1.77
The ATHEROMA (Atorvastatin Therapy: Effects on Reduction of Macrophage Activity) Study. Evaluation using ultrasmall superparamagnetic iron oxide-enhanced magnetic resonance imaging in carotid disease. J Am Coll Cardiol (2009) 1.76
Targeting atherosclerosis by using modular, multifunctional micelles. Proc Natl Acad Sci U S A (2009) 1.76
Beyond restenosis: five-year clinical outcomes from second-generation coronary stent trials. Circulation (2004) 1.72
Biocompatible luminescent silicon quantum dots for imaging of cancer cells. ACS Nano (2008) 1.71
Macrophage scavenger receptors and host-derived ligands. Methods (2007) 1.69
Microfluidic single-cell array cytometry for the analysis of tumor apoptosis. Anal Chem (2009) 1.68
Targeted molecular probes for imaging atherosclerotic lesions with magnetic resonance using antibodies that recognize oxidation-specific epitopes. Circulation (2008) 1.68
Atherothrombosis and high-risk plaque: Part II: approaches by noninvasive computed tomographic/magnetic resonance imaging. J Am Coll Cardiol (2005) 1.67
Matrix metalloproteinase-9 is required for adequate angiogenic revascularization of ischemic tissues: potential role in capillary branching. Circ Res (2003) 2.51
Routine intraoperative completion angiography after coronary artery bypass grafting and 1-stop hybrid revascularization results from a fully integrated hybrid catheterization laboratory/operating room. J Am Coll Cardiol (2009) 2.40
A blood-based gene expression test for obstructive coronary artery disease tested in symptomatic nondiabetic patients referred for myocardial perfusion imaging the COMPASS study. Circ Cardiovasc Genet (2013) 2.18
Hyperoxia is associated with increased mortality in patients treated with mild therapeutic hypothermia after sudden cardiac arrest. Crit Care Med (2012) 1.65
Vascular oxidant stress enhances progression and angiogenesis of experimental atheroma. Circulation (2004) 1.50
Comparison between visual assessment and quantitative angiography versus fractional flow reserve for native coronary narrowings of moderate severity. Am J Cardiol (2002) 1.15
Ex vivo red blood cell hemolysis assay for the evaluation of pH-responsive endosomolytic agents for cytosolic delivery of biomacromolecular drugs. J Vis Exp (2013) 1.08
Characterization of the degradation mechanisms of lysine-derived aliphatic poly(ester urethane) scaffolds. Biomaterials (2010) 1.08
Characterization of superparamagnetic nanoparticle interactions with extracellular matrix in an in vitro system. Ann Biomed Eng (2006) 1.04
Proteolytic surface functionalization enhances in vitro magnetic nanoparticle mobility through extracellular matrix. Nano Lett (2006) 1.04
Combinatorial polymer electrospun matrices promote physiologically-relevant cardiomyogenic stem cell differentiation. PLoS One (2011) 0.99
Characteristics and clinical significance of angiographically mild lesions in acute coronary syndromes. JACC Cardiovasc Imaging (2012) 0.99
Engineering complement activation on polypropylene sulfide vaccine nanoparticles. Biomaterials (2010) 0.98
Macrophage-specific RNA interference targeting via "click", mannosylated polymeric micelles. Mol Pharm (2013) 0.98
Whole blood gene expression testing for coronary artery disease in nondiabetic patients: major adverse cardiovascular events and interventions in the PREDICT trial. J Cardiovasc Transl Res (2012) 0.97
Size- and charge-dependent non-specific uptake of PEGylated nanoparticles by macrophages. Int J Nanomedicine (2012) 0.95
Quantum dot self-assembly for protein detection with sub-picomolar sensitivity. Langmuir (2008) 0.95
Neurovascular unit on a chip: implications for translational applications. Stem Cell Res Ther (2013) 0.94
Pro-angiogenic and anti-inflammatory regulation by functional peptides loaded in polymeric implants for soft tissue regeneration. Tissue Eng Part A (2012) 0.93
Risk stratification in acute heart failure: rationale and design of the STRATIFY and DECIDE studies. Am Heart J (2012) 0.92
Hyperacute lung rejection in the pig-to-human model. III. Platelet receptor inhibitors synergistically modulate complement activation and lung injury. Transplantation (2003) 0.89
Three-dimensional graphene foams promote osteogenic differentiation of human mesenchymal stem cells. Nanoscale (2013) 0.88
Biological and analytical stability of a peripheral blood gene expression score for obstructive coronary artery disease in the PREDICT and COMPASS studies. J Cardiovasc Transl Res (2014) 0.88
Physiologically relevant oxidative degradation of oligo(proline) cross-linked polymeric scaffolds. Biomacromolecules (2011) 0.87
Dual MMP7-proximity-activated and folate receptor-targeted nanoparticles for siRNA delivery. Biomacromolecules (2014) 0.87
Modular polymer design to regulate phenotype and oxidative response of human coronary artery cells for potential stent coating applications. Acta Biomater (2011) 0.85
Passage-dependent cancerous transformation of human mesenchymal stem cells under carcinogenic hypoxia. FASEB J (2013) 0.84
Non-fibroatheroma lesion phenotype and long-term clinical outcomes: a substudy analysis from the PROSPECT study. JACC Cardiovasc Imaging (2013) 0.84
Cell interaction study method using novel 3D silica nanoneedle gradient arrays. Colloids Surf B Biointerfaces (2012) 0.83
Implementation of a standardized pathway for the treatment of cardiac arrest patients using therapeutic hypothermia: "CODE ICE". Crit Pathw Cardiol (2012) 0.82
Galectin 3 complements BNP in risk stratification in acute heart failure. Biomarkers (2012) 0.82
Current progress in Reactive Oxygen Species (ROS)-Responsive materials for biomedical applications. Adv Healthc Mater (2013) 0.81
Decoupling polymer properties to elucidate mechanisms governing cell behavior. Tissue Eng Part B Rev (2012) 0.81
Proximity-activated nanoparticles: in vitro performance of specific structural modification by enzymatic cleavage. Int J Nanomedicine (2008) 0.80
Superparamagnetic nanoparticles as a powerful systems biology characterization tool in the physiological context. Angew Chem Int Ed Engl (2008) 0.80
Enzymatic- and temperature-sensitive controlled release of ultrasmall superparamagnetic iron oxides (USPIOs). J Nanobiotechnology (2011) 0.79
Interplay of anionic charge, poly(ethylene glycol), and iodinated tyrosine incorporation within tyrosine-derived polycarbonates: Effects on vascular smooth muscle cell adhesion, proliferation, and motility. J Biomed Mater Res A (2010) 0.78
UV laser-ablated surface textures as potential regulator of cellular response. Biointerphases (2010) 0.78
Biocompatible mannosylated endosomal-escape nanoparticles enhance selective delivery of short nucleotide sequences to tumor associated macrophages. Nanoscale (2015) 0.78
Liposomal entrapment of cefoxitin to improve cellular viability and function in human saphenous veins. Artif Organs (2003) 0.78
Poly(ε-caprolactone)-carbon nanotube composite scaffolds for enhanced cardiac differentiation of human mesenchymal stem cells. Nanomedicine (Lond) (2013) 0.78
High-content profiling of cell responsiveness to graded substrates based on combinyatorially variant polymers. Comb Chem High Throughput Screen (2009) 0.78
DNA delivery to cells in culture using cationic liposomes. Methods Mol Biol (2004) 0.77
Profiling cell-biomaterial interactions via cell-based fluororeporter imaging. Biotechniques (2007) 0.76
Repairing Fetal Membranes with a Self-adhesive Ultrathin Polymeric Film: Evaluation in Mid-gestational Rabbit Model. Ann Biomed Eng (2014) 0.76
Elucidation of adhesion-dependent spontaneous apoptosis in macrophages using phase separated PEG/polyurethane films. Acta Biomater (2012) 0.76
A comparison of criterion standard methods to diagnose acute heart failure. Congest Heart Fail (2012) 0.76
The multistrata nanoparticle: an FeOx/Au core/shell enveloped in a silica-Au shell. Small (2011) 0.76
Vulnerable plaque intervention: State of the art. Catheter Cardiovasc Interv (2008) 0.75
In vitro bioassay of endotoxin using fluorescein as a pH indicator in a macrophage cell culture system. Yonsei Med J (2005) 0.75
The authors reply. Crit Care Med (2013) 0.75
The authors reply. Crit Care Med (2013) 0.75
Stem cell therapy for chronic heart failure: an updated appraisal. Expert Opin Biol Ther (2013) 0.75
2015 ACC/AHA/HRS Advanced Training Statement on Clinical Cardiac Electrophysiology (A Revision of the ACC/AHA 2006 Update of the Clinical Competence Statement on Invasive Electrophysiology Studies, Catheter Ablation, and Cardioversion). Circ Arrhythm Electrophysiol (2015) 0.75
Acute coronary syndrome pathways: alignment with a bundled care reimbursement model. Crit Pathw Cardiol (2011) 0.75
Quantification of quantum dot concentration using inductively coupled plasma-mass spectrometry (ICP-MS). J Biomed Nanotechnol (2011) 0.75
Tunable Surface Repellency Maintains Stemness and Redox Capacity of Human Mesenchymal Stem Cells. ACS Appl Mater Interfaces (2017) 0.75
Therapeutic procedures for coronary vasospasm-induced polymorphic ventricular tachycardia. Ther Adv Cardiovasc Dis (2012) 0.75
Lumen Measurements From Quantitative Coronary Angiography and IVUS: A PROSPECT Substudy. JACC Cardiovasc Imaging (2015) 0.75
2016 ACC Lifelong Learning Competencies for General Cardiologists: A Report of the ACC Competency Management Committee. J Am Coll Cardiol (2016) 0.75
COCATS 4 Task Force 12: Training in Heart Failure. J Am Coll Cardiol (2015) 0.75
Combined usage of stem cells in end-stage heart failure therapies. J Cell Biochem (2014) 0.75